We first confirmed that anti-hPD-L1 mAb without modification or radiolabeling had no impact on tumor growth or survival in our preclinical melanoma model by treating M113PD-L1+ melanoma tumor bearing mice with 20 and 100 μg of mAb, which were, respectively, 3- to 16-fold the amount of mAb used in TAT experiments (Figure S3). This evidence concerns the gene CD274 and neoplasm.